Literature DB >> 8666940

Inhibition of interleukin-1 responsiveness by type II receptor gene transfer: a surface "receptor" with anti-interleukin-1 function.

F Re1, M Sironi, M Muzio, C Matteucci, M Introna, S Orlando, G Penton-Rol, S K Dower, J E Sims, F Colotta, A Mantovani.   

Abstract

The hypothesis that the type II receptor (RII) acts as a decoy for interleukin-1 (IL-1) was tested by gene transfer in cells expressing only the type I receptor (8387 fibroblasts). RII-transfected cells showed defective responsiveness to IL-1 in terms of NFkappaB activation, cytokine gene expression and production. Blocking monoclonal antibodies against RII restored the capacity of RII-transfected cells to respond to IL-1 beta. Hence defective IL-1 responsiveness of RII-transfected cells requires surface expression of the molecule. RII-transfected cells showed normal responsiveness to TNF, which shares functional properties and elements in the signal transduction pathway with IL-1. Cells transfected with a deletion mutant of RII missing 26 of 29 amino acids of the cytoplasmic portion of the molecule showed impaired responsiveness to IL-2. Cells transfected with full-length or the cytoplasmic deletion mutant of RII released copious amounts of RII in the supernatant. However, transfected cells showed defective responsiveness to brief exposure to IL-1, in the absence of measurable released RII. These results indicate that impairment of the responsiveness to IL-1 following RII gene transfer was dependent upon surface expression of the molecule, specific for IL-1 and unaffected by truncation of the cytoplasmic portion. Thus, the type II "receptor" is a decoy surface molecule, regulated by antiinflammatory signals, whose only known function is to capture and block IL-1.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8666940      PMCID: PMC2192538          DOI: 10.1084/jem.183.4.1841

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  51 in total

1.  cDNA cloning of an intracellular form of the human interleukin 1 receptor antagonist associated with epithelium.

Authors:  S Haskill; G Martin; L Van Le; J Morris; A Peace; C F Bigler; G J Jaffe; C Hammerberg; S A Sporn; S Fong
Journal:  Proc Natl Acad Sci U S A       Date:  1991-05-01       Impact factor: 11.205

2.  A soluble form of the interleukin-1 receptor produced by a human B cell line.

Authors:  J A Symons; G W Duff
Journal:  FEBS Lett       Date:  1990-10-15       Impact factor: 4.124

3.  A soluble binding protein specific for interleukin 1 beta is produced by activated mononuclear cells.

Authors:  J A Symons; J A Eastgate; G W Duff
Journal:  Cytokine       Date:  1990-05       Impact factor: 3.861

4.  Two different cell types have different major receptors for human tumor necrosis factor (TNF alpha).

Authors:  H P Hohmann; R Remy; M Brockhaus; A P van Loon
Journal:  J Biol Chem       Date:  1989-09-05       Impact factor: 5.157

5.  Coordinated antiinflammatory effects of interleukin 4: interleukin 4 suppresses interleukin 1 production but up-regulates gene expression and synthesis of interleukin 1 receptor antagonist.

Authors:  E Vannier; L C Miller; C A Dinarello
Journal:  Proc Natl Acad Sci U S A       Date:  1992-05-01       Impact factor: 11.205

6.  Phosphorylation of the small heat-shock protein is regulated by interleukin 1, tumour necrosis factor, growth factors, bradykinin and ATP.

Authors:  J Saklatvala; P Kaur; F Guesdon
Journal:  Biochem J       Date:  1991-08-01       Impact factor: 3.857

Review 7.  Interleukin-1 and interleukin-1 antagonism.

Authors:  C A Dinarello
Journal:  Blood       Date:  1991-04-15       Impact factor: 22.113

8.  Endothelial cells express the interleukin-1 receptor type I.

Authors:  D Boraschi; A Rambaldi; A Sica; P Ghiara; F Colotta; J M Wang; M de Rossi; C Zoia; G Remuzzi; F Bussolino
Journal:  Blood       Date:  1991-09-01       Impact factor: 22.113

9.  Purification and characterization of a novel soluble receptor for interleukin 1.

Authors:  J A Symons; J A Eastgate; G W Duff
Journal:  J Exp Med       Date:  1991-11-01       Impact factor: 14.307

10.  A novel IL-1 receptor, cloned from B cells by mammalian expression, is expressed in many cell types.

Authors:  C J McMahan; J L Slack; B Mosley; D Cosman; S D Lupton; L L Brunton; C E Grubin; J M Wignall; N A Jenkins; C I Brannan
Journal:  EMBO J       Date:  1991-10       Impact factor: 11.598

View more
  24 in total

Review 1.  Humoral sleep regulation; interleukin-1 and tumor necrosis factor.

Authors:  Kathryn A Jewett; James M Krueger
Journal:  Vitam Horm       Date:  2012       Impact factor: 3.421

Review 2.  The interleukin-1 family: back to the future.

Authors:  Cecilia Garlanda; Charles A Dinarello; Alberto Mantovani
Journal:  Immunity       Date:  2013-12-12       Impact factor: 31.745

Review 3.  The interplay between primary and secondary cytokines. Cytokines involved in the regulation of monocyte recruitment.

Authors:  A Mantovani
Journal:  Drugs       Date:  1997       Impact factor: 9.546

4.  Keratinocyte expression of the type 2 interleukin 1 receptor mediates local and specific inhibition of interleukin 1-mediated inflammation.

Authors:  T Rauschmayr; R W Groves; T S Kupper
Journal:  Proc Natl Acad Sci U S A       Date:  1997-05-27       Impact factor: 11.205

5.  Preferential localization of systemically administered radiolabeled interleukin 1alpha in experimental inflammation in mice by binding to the type II receptor.

Authors:  C J van der Laken; O C Boerman; W J Oyen; M T van de Ven; R Chizzonite; F H Corstens; J W van der Meer
Journal:  J Clin Invest       Date:  1997-12-15       Impact factor: 14.808

6.  Kinetic approach to pathway attenuation using XOMA 052, a regulatory therapeutic antibody that modulates interleukin-1beta activity.

Authors:  Marina K Roell; Hassan Issafras; Robert J Bauer; Kristen S Michelson; Nerissa Mendoza; Sandra I Vanegas; Lisa M Gross; Paul D Larsen; Daniel H Bedinger; David J Bohmann; Genevieve H Nonet; Naichi Liu; Steve R Lee; Masahisa Handa; Seema S Kantak; Arnold H Horwitz; John J Hunter; Alexander M Owyang; Amer M Mirza; John A Corbin; Mark L White
Journal:  J Biol Chem       Date:  2010-04-21       Impact factor: 5.157

Review 7.  Interleukin-1 function and role in rheumatic disease.

Authors:  Georg Schett; Jean-Michel Dayer; Bernhard Manger
Journal:  Nat Rev Rheumatol       Date:  2015-12-10       Impact factor: 20.543

8.  MARCH3 attenuates IL-1β-triggered inflammation by mediating K48-linked polyubiquitination and degradation of IL-1RI.

Authors:  Heng Lin; Deng Gao; Ming-Ming Hu; Man Zhang; Xiao-Xia Wu; Lu Feng; Wen-Hua Xu; Qing Yang; Xuan Zhong; Jin Wei; Zhi-Sheng Xu; Hong-Xia Zhang; Ze-Min Song; Qian Zhou; Wen Ye; Ying Liu; Shu Li; Hong-Bing Shu
Journal:  Proc Natl Acad Sci U S A       Date:  2018-11-15       Impact factor: 11.205

Review 9.  Regulation of IL-1 signaling by the decoy receptor IL-1R2.

Authors:  Thomas Schlüter; Carsten Schelmbauer; Khalad Karram; Ilgiz A Mufazalov
Journal:  J Mol Med (Berl)       Date:  2018-08-15       Impact factor: 4.599

Review 10.  Tuning inflammation and immunity by the negative regulators IL-1R2 and IL-1R8.

Authors:  Martina Molgora; Domenico Supino; Alberto Mantovani; Cecilia Garlanda
Journal:  Immunol Rev       Date:  2018-01       Impact factor: 12.988

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.